The Forbes Institute for Cancer Discovery at the University of Michigan has announced its first round of grant recipients, with $500,000 earmarked to undertake high-risk, high-reward initiatives with the potential to drive new advances in cancer research.
Health coalition forms National Lung Cancer Roundtable to increase screening, reduce lung cancer deaths
The American Cancer Society and a coalition of leading professional, government and non-governmental organizations are coming together to form the National Lung Cancer Roundtable to accelerate the nation’s efforts to reduce mortality from lung cancer.
When small-molecule inhibitors proved elusive, researchers developed a novel strategy: Using large molecule peptides to target a common prostate cancer driver. It may provide a path for developing new therapies against a challenging target.
Revised understanding of graft-versus-host disease origins offers new direction for potential therapies
An international research team led by the University of Michigan Life Sciences Institute is changing the understanding of the key cellular and molecular events that trigger graft-versus-host disease, an often-fatal complication of bone marrow transplants.
Fewer than three out of five women with cervical cancer received guideline-based care, a new study finds. For black and Hispanic women, it’s just over half, which could help explain why cervical cancer outcomes tend to be worse for these women.
It’s well known that women with certain hereditary genetic mutations, particularly BRCA1 and BRCA2, have an increased risk of breast cancer. But in recent years, researchers have discovered a link between some of those same genetic mutations – along with a handful of others – and aggressive prostate cancer.
A new study from researchers at the University of Michigan Comprehensive Cancer Center identifies a protein in that microenvironment that promotes the spread of breast cancer cells. It’s part of a well-known family of receptors for which promising inhibitors are being developed.
Nearly one-third of early stage breast cancer patients overestimate their risk of cancer recurrence — believing it to be more than double their actual risk. And that overestimation is affecting their quality of life, according to two recent studies. The good news? A more nuanced approach to doctor-patient communication may help improve patients’ understanding.
Physicians often fail to recommend genetic testing for breast cancer patients at high risk for mutations associated with ovarian and other cancers, according to a new study.
After a decade of using a novel approach to select patients for laryngeal cancer treatment, researchers are reporting "exceptional" survival rates nearing 80 percent, even for the most advanced patients.